These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Clinical pharmacokinetics of the depot antipsychotics. Jann MW; Ereshefsky L; Saklad SR Clin Pharmacokinet; 1985; 10(4):315-33. PubMed ID: 2864156 [TBL] [Abstract][Full Text] [Related]
4. Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations. Knudsen P Acta Psychiatr Scand Suppl; 1985; 322():51-75. PubMed ID: 2866666 [TBL] [Abstract][Full Text] [Related]
5. Simultaneous UPLC-MS/MS assay for the detection of the traditional antipsychotics haloperidol, fluphenazine, perphenazine, and thiothixene in serum and plasma. Juenke JM; Brown PI; Urry FM; Johnson-Davis KL; McMillin GA Clin Chim Acta; 2013 Aug; 423():32-4. PubMed ID: 23618971 [TBL] [Abstract][Full Text] [Related]
6. Quantitation of Haloperidol, Fluphenazine, Perphenazine, and Thiothixene in Serum or Plasma Using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). Slawson MH; Johnson-Davis KL Methods Mol Biol; 2016; 1383():49-57. PubMed ID: 26660173 [TBL] [Abstract][Full Text] [Related]
7. Neuroleptic plasma levels. Van Putten T; Marder SR; Wirshing WC; Aravagiri M; Chabert N Schizophr Bull; 1991; 17(2):197-216. PubMed ID: 1679251 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of neuroleptic drugs and the utility of plasma level monitoring. Dahl SG Psychopharmacol Ser; 1988; 5():34-46. PubMed ID: 2901082 [TBL] [Abstract][Full Text] [Related]
9. Plasma level monitoring of antipsychotic drugs. Cooper TB Clin Pharmacokinet; 1978; 3(1):14-38. PubMed ID: 25154 [TBL] [Abstract][Full Text] [Related]
10. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346 [TBL] [Abstract][Full Text] [Related]
11. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. El Ela AA; Härtter S; Schmitt U; Hiemke C; Spahn-Langguth H; Langguth P J Pharm Pharmacol; 2004 Aug; 56(8):967-75. PubMed ID: 15285840 [TBL] [Abstract][Full Text] [Related]
12. [Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics]. Levron JC; Ropert R Encephale; 1987; 13(2):83-7. PubMed ID: 2885172 [TBL] [Abstract][Full Text] [Related]
13. Within-individual variation in steady state plasma levels of different neuroleptics and prolactin. McCreadie RG; Mackie M; Wiles DH; Jorgensen A; Hansen V; Menzies C Br J Psychiatry; 1984 Jun; 144():625-9. PubMed ID: 6146373 [TBL] [Abstract][Full Text] [Related]
14. Screening, library-assisted identification and validated quantification of fifteen neuroleptics and three of their metabolites in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization. Kratzsch C; Peters FT; Kraemer T; Weber AA; Maurer HH J Mass Spectrom; 2003 Mar; 38(3):283-95. PubMed ID: 12644990 [TBL] [Abstract][Full Text] [Related]
15. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Altamura AC; Sassella F; Santini A; Montresor C; Fumagalli S; Mundo E Drugs; 2003; 63(5):493-512. PubMed ID: 12600227 [TBL] [Abstract][Full Text] [Related]
16. [Relations between the levels of neuroleptics and the doses, the therapeutic effects and the side effects]. Davy JP; Moulin M; Andersson JC; Halbecq JJ; Morel P; Poilpre E Encephale; 1978; 4(4):293-321. PubMed ID: 33791 [TBL] [Abstract][Full Text] [Related]
17. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. Herrick-Davis K; Grinde E; Teitler M J Pharmacol Exp Ther; 2000 Oct; 295(1):226-32. PubMed ID: 10991983 [TBL] [Abstract][Full Text] [Related]